A new day for drug development in neuroscience
National Institutes of Health
Dr. Dolmetsch’s group is responsible for leveraging advances in human genetics to model and treat neuropsychiatric and neurodegenerative diseases. Areas of focus include genomics, induced pluripotent stem cells, and brain circuitry. Dr. Dolmetsch joined Novartis in August 2013 from the Stanford University School of Medicine, where he was an associate professor of neurobiology. He was also the senior director of Molecular Networks at the Allen Institute for Brain Research. He studied the molecular roots of autism and other neurodevelopmental disorders, including the role of calcium-channel signaling. His laboratory recently used induced pluripotent stem cells to develop an in vitro model of Timothy syndrome, a rare disease with a variety of symptoms, including the characteristic features of autism.